Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: A case series and literature review

The V-CHG regimen, combining venetoclax, cytarabine, homoharringtonine, and G-CSF, showed promising efficacy and safety in treating three patients with refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia. All cases achieved complete remission, with adverse events being tolerable. These preliminary results suggest the regimen's potential for future application.